Sureda Anna, Pavlovsky Astrid, Haidar Dalah, Kristo Fjoralba, Stache Vanessa, Zomas Athanasios
Institut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
FUNDALEU Research Center, Buenos Aires, Argentina.
Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557-7.
Brentuximab vedotin (BV) as post-autologous stem cell transplantation (ASCT) consolidation was shown to reduce the relapse risk among high-risk patients with relapsed/refractory Hodgkin lymphoma (RRHL) in the clinical trial setting. This systematic review and meta-analysis characterizes real-world evidence (RWE) on the effectiveness and safety of BV as post-ASCT consolidation in 1504 adult and pediatric patients with RRHL from 23 studies across 17 countries. A random-effects model yielded pooled progression-free survival (PFS) and overall survival rates (OS); PFS: 2-year, 74.2%; 5-year, 65.8%; OS: 2-year, 95.8%; 5-year, 91.9%. The most common any-grade adverse events were neuropathy (34.2%) and neutropenia (20.2%). Despite heterogeneity in populations and outcomes, this analysis utilizing real-world data corroborates the efficacy and safety of BV as post-ASCT consolidation in RRHL reported in the experimental arm of the Phase III AETHERA trial. The favorable PFS results in cases exposed to BV prior to ASCT indicate the value of BV in controlling Hodgkin lymphoma (HL) in the salvage setting. Continued research is essential to refine BV treatment strategies amid the evolving treatment landscape.
在临床试验中，显示布罗达单抗（BV）作为自体干细胞移植（ASCT）后的巩固治疗可降低复发/难治性霍奇金淋巴瘤（RRHL）高危患者的复发风险。本系统评价和荟萃分析描述了来自17个国家23项研究的1504例成年和儿科RRHL患者中，BV作为ASCT后巩固治疗的有效性和安全性的真实世界证据（RWE）。随机效应模型得出汇总的无进展生存率（PFS）和总生存率（OS）；PFS：2年，74.2%；5年，65.8%；OS：2年，95.8%；5年，91.9%。最常见的任何级别不良事件为神经病变（34.2%）和中性粒细胞减少（20.2%）。尽管人群和结局存在异质性，但本利用真实世界数据的分析证实了BV作为RRHL患者ASCT后巩固治疗的有效性和安全性，这与III期AETHERA试验实验组报告的结果一致。在ASCT前接受BV治疗的病例中，良好的PFS结果表明BV在挽救治疗中控制霍奇金淋巴瘤（HL）的价值。在不断演变的治疗格局中，持续研究对于完善BV治疗策略至关重要。
